TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03918278

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-0482
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-0482
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-0482
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-0482
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-0482
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-0482
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-0482
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion
Study: NCT03832504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: The participant will rest in a seated position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: The participant will rest in a seated position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fan
Description: A fan placed in front of the participant will provide an airflow of 4 m/s throughout the exposure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Wetting
Description: Tap water (\~18°C) will be applied every 5 minutes to the face, neck, upper and lower arms and upper and lower legs using a spray bottle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Wetting
Description: Tap water (\~18°C) will be applied every 5 minutes to the face, neck, upper and lower arms and upper and lower legs using a spray bottle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fan + Skin wetting
Description: A fan placed in front of the participant will provide an airflow of 4 m/s throughout the exposure. In addition, tap water (\~18°C) will be applied every 5 minutes to the face, neck, upper and lower arms and upper and lower legs using a spray bottle.
Study: NCT00776802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCS-100
Description: GCS-100 80 mg/m2 IV (in the vein) on Study Days 1, 2, 3, 4, and 5 of a 21-day course. Three or up to six patients will be enrolled in each cohort until the maximum tolerated dose is reached. The dose levels: 1) 80 mg/m2; 2) 120 mg/m2; 3) 160 mg/m2
Study: NCT04593706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone acetate
Description: the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone acetate
Description: the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Description: the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Description: the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar
Study: NCT01300078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF101
Description: MF101 10 g/day MF101 15 g/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF101
Description: MF101 10 g/day MF101 15 g/day
Study: NCT04346485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SP TFL RIRS with 145 mcm fiber
Description: retrograde intrarenal surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SP TFL RIRS with 200 mcm fiber
Description: retrograde intrarenal surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ho:YAG RIRS with 200 mcm fiber
Description: retrograde intrarenal surgery
Study: NCT02828163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Platelet rich plasma
Description: Intralesional injection of 1 milliliter of autologous Platelet rich plasma in the oral erosions every 2 weeks for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: 10mg/ml of Triamcinolone acetonide will be injected in one side of the oral mucosa of pemphigus vulgaris patients every 2 weeks for 3 months.
Study: NCT00705562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: milk protein formulas, varying carbohydrate/protein sources
Description: ad lib for 0-8 days of age until 28 days of age

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: milk protein formulas, varying carbohydrate/protein sources
Description: ad lib for 0-8 days of age until 28 days of age

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: milk protein formulas, varying carbohydrate/protein sources
Description: ad lib for 0-8 days of age until 28 days of age

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: milk protein formulas, varying carbohydrate/protein sources
Description: ad lib for 0-8 days of age until 28 days of age

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: milk protein formulas, varying carbohydrate/protein sources
Description: ad lib for 0-8 days of age until 28 days of age
Study: NCT00776802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide; Dexamethasone
Description: Etoposide 100 mg/m2 on Study Days 3, 4 and 5; Dexamethasone 10 mg/m2 on Study Days 1, 2, 3, 4 and 5.
Study: NCT02669134

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Device programming
Description: SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed AV+VV
Study: NCT04224220

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adult Medical Care Coordination
Description: Nurse-based support that includes a home visit and follow-up coaching telephone calls to monitor patient status and ability to self-manage symptoms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Patient Monitoring
Description: Nurse-based support and coaching that incorporates the use of technology to monitor patient status and ability to self-manage symptoms.
Study: NCT01858623

Intervention type: DRUG
Group type: OTHER
Intervention: Losartan/hydrochlorothiazide

Intervention type: DRUG
Group type: OTHER
Intervention: Losartan

Intervention type: DRUG
Group type: OTHER
Intervention: Hydrochlorothiazide
Study: NCT03555942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follicular phase corifollitropin alfa
Description: GnRH antagonist protocol with corifollitropin alfa initiated in the follicular phase (day 2 or 3 of the menstrual cycle)
Study: NCT02669134

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Device programming
Description: SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed AV+VV
Study: NCT03555942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteal phase corifollitropin alfa
Description: GnRH antagonist protocol with corifollitropin alfa initiated in the luteal phase (5 days after an LH peak)
Study: NCT03411798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yisaipu®
Description: Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR \& CRP reduce to normal and BASDAI\<4) maintenance.
Study: NCT01402505

Intervention type: PROCEDURE
Intervention: Transvaginal NOTES sleeve gastrectomy
Description: transvaginal NOTES sleeve gastrectomy
Study: NCT04523870

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Botanical extract
Description: One capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Main compound of the botanical extract
Description: one capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin, one capsule
Study: NCT06731543

Intervention type: OTHER
Intervention: No interventions will be made
Study: NCT02209025

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Theobromine
Description: Theobromine a compound for cocoa

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Study: NCT02623842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tonederm® (Radiofrequency non ablative)
Description: The application of RF was performed by physical therapist trained in the technique of radio frequency through the Tonederm® brand device with capacitive transfer method using non-ablative handle with electrode in the region of the external urethral meatro and coupling electrode placed on the participant's back. For application, the participants were in gynecological position. The session had an average duration of 20 minutes. The temperature was measured by an infrared thermometer when it reached 41graus radiofrequency was maintained for 2 minutes.
Study: NCT04577222

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Technical modification during radical prostatectomy
Description: Covering the NVB with fat
Study: NCT03913104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Patients will have MifeprexⓇ (mifepristone) shipped to a preferred address via an online mail order pharmacy rather than standard care at clinic visit.
Study: NCT04151745

Intervention type: PROCEDURE
Group type: OTHER
Intervention: external pacemaker switched off
Description: When a hemodynamically stable state is achieved, the external pacemaker will be switched off for 30 minutes. Hemodynamic parameters will be acquired directly prior to switching off, 15 respectively 30 minutes after switching off, and 15 minutes after switching back on. To gain insight in the natural course of stunning, this routine will be repeated the next morning.
Study: NCT04332731

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symplicity Spyral™ multi electrode renal denervation system
Description: Symplicity Spyral™ multi-electrode renal denervation catheter (Symplicity Spyral catheter, Medtronic) and associated Symplicity G3™ renal denervation radiofrequency generator (Symplicity G3 generator, Medtronic) will be used in this study. The Symplicity Spyral™ multi-electrode renal denervation catheter is intended to deliver low-level radio frequency (RF) energy through the wall of the renal artery to denervate the human kidney.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Renal angiogram
Description: Renal angiogram will be used in both treatment and sham groups. Renal angiography is an imaging test used to study the blood vessels in the kidneys. The test will examine the kidney artery anatomy using x-rays following the injection of an x-ray dye (contrast medium). Only patients with eligible renal artery anatomy (between 3 mm and 8 mm) will be randomized ( to treatment or sham groups).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Renal angiogram
Description: Renal angiogram will be used in both treatment and sham groups. Renal angiography is an imaging test used to study the blood vessels in the kidneys. The test will examine the kidney artery anatomy using x-rays following the injection of an x-ray dye (contrast medium). Only patients with eligible renal artery anatomy (between 3 mm and 8 mm) will be randomized ( to treatment or sham groups).
Study: NCT03472313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-958
Description: Healthy Volunteers recruited for the study will undergo a single \[18F\]MNI-958 injection and PET scan.
Study: NCT04986943

Intervention type: DEVICE
Intervention: Using ABTHERA Advance without a Wittmann Patch
Description: In this group, patients will be receiving only the ABTHERA Advance product, without the use of the Wittmann Patch
Study: NCT03573401

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)
Description: The Main Target Lesion will be marked by at least 3 ink marks prior to PDT to enable precise excision for histopathological assessment 12 weeks after the first or second PDT cycle dependent on the clearance status of the lesion. All target lesions should be prepared prior to drug application by degreasing, removal of all scabs and crusts, and roughening of the surface, if appropriate. Bleeding should be avoided. The formulations will then be applied to the lesions (maximal combined lesion area incl. margin is 20 cm²) located in 1 to 2 illumination areas. The medication should be applied to the entire lesion(s) plus a 0.5 - 1.0 cm margin surrounding each lesion at a thickness of 1 mm, allowed to dry (for approximately 10 minutes), covered with occlusive dressing, and incubated for approximately 3 h. Thereafter, any remnants of the IMP will be removed carefully and the PDT illumination will be administered using the light emitting diode (LED) red light device BF-RhodoLED®.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Description: The Main Target Lesion will be marked by at least 3 ink marks prior to PDT to enable precise excision for histopathological assessment 12 weeks after the first or second PDT cycle dependent on the clearance status of the lesion. All target lesions should be prepared prior to drug application by degreasing, removal of all scabs and crusts, and roughening of the surface, if appropriate. Bleeding should be avoided. The formulations will then be applied to the lesions (maximal combined lesion area incl. margin is 20 cm²) located in 1 to 2 illumination areas. The medication should be applied to the entire lesion(s) plus a 0.5 - 1.0 cm margin surrounding each lesion at a thickness of 1 mm, allowed to dry (for approximately 10 minutes), covered with occlusive dressing, and incubated for approximately 3 h. Thereafter, any remnants of the IMP will be removed carefully and the PDT illumination will be administered using the light emitting diode (LED) red light device BF-RhodoLED®.
Study: NCT01535586

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP versus MAD
Description: Cross over design

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP versus MAD
Description: Cross over design
Study: NCT01285492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 (110 μg indacaterol / 50 μg glycopyrronium o.d.), delivered via Concept1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium (18 μg o.d.), delivered via Handihaler®
Study: NCT02785276

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: AutoFuser Pain Pump
Description: Closed loop local anaesthetic infusion system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoFuser Pain Pump
Description: Closed loop local anaesthetic infusion system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Commonly used local anaesthetic drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (0.9%)
Description: Normal saline is a sterile, non-pyrogenic solution for fluid and electrolyte replenishment for intravenous administration. This will be the solution used for the intraperitoneal infusion in the placebo/control group.
Study: NCT00840671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline Solution
Description: 0.9% Saline Solution, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
Study: NCT00634920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus (Certican®) tablets administered orally in two divided doses (b.i.d.) at a starting dose of 4 mg/day adjusted to target a trough blood concentration between 6 and 10 ng/mL in period 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine A
Description: CsA (Sandimmun Neoral), based on C0-h levels 75-200 ng/mL or C2-h levels 700 900 ng/mL from randomization to Month 6, or C0-h levels 50-150 ng/mL or C2-h levels 600 800 ng/mL from Month 6 to Month 36, according to local method

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric Coated Mycophenolate Sodium (EC-MPS)
Description: Target dose 1440 mg in the control group, target dose 1080 in the everolimus group (higher dose in the CsA group because of interactions of CsA on gastric reabsorption of mycophenolate)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric Coated Mycophenolate Sodium (EC-MPS)
Description: Target dose 1440 mg in the control group, target dose 1080 in the everolimus group (higher dose in the CsA group because of interactions of CsA on gastric reabsorption of mycophenolate)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: For both groups: minimum corticosteroid dose of 10 mg until week 12, 5-10 mg until month 12, month 12-36 corticosteroid treatment on investigator's descretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: For both groups: minimum corticosteroid dose of 10 mg until week 12, 5-10 mg until month 12, month 12-36 corticosteroid treatment on investigator's descretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: Induction therapy 20 mg basiliximab on Day 0 prior to reperfusion and 20 mg on Day 4 post-TX.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Induction therapy 20 mg basiliximab on Day 0 prior to reperfusion and 20 mg on Day 4 post-TX.
Study: NCT03181906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-Consultation Medication Reconciliation
Description: Medication reconciliation service to be done for participants randomised to the intervention group
Study: NCT04260399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender Aromatherapy
Description: Participants in the experimental group will be passively exposed to lavender essential oil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Aromatherapy
Description: Participants in the control group will be passively exposed to saline water aromatherapy
Study: NCT04353817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination tablet for oral administration qd in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration qd in the evening.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to ELX/TEZ/IVA)
Description: Placebo matched to ELX/TEZ/IVA for oral administration once daily (qd) in the morning.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to IVA)
Description: Placebo matched to IVA for oral administration qd in the evening.
Study: NCT03849768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10296
Description: Drug: HS-10296 110 mg/55 mg + placebo The initial dose of HS-10296 110 mg once daily can be reduced to 55 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: Drug: Gefitinib 250 mg + placebo The initial dose of Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study: NCT06382571

Intervention type: DRUG
Intervention: Renin-Angiotensin System Inhibitor

Intervention type: DRUG
Intervention: Renin-Angiotensin System Inhibitor
Study: NCT03344406

Intervention type: OTHER
Intervention: Telephonic interviews
Description: Qualitative concept elicitation telephone interviews will be conducted in subjects with asthma.

Intervention type: OTHER
Intervention: E-RS: COPD
Description: E-RS questionnaire will directly measure respiratory symptom severity.

Intervention type: OTHER
Intervention: Supplemental asthma items
Description: Supplemental asthma items will include one question on wheeze and an item on breathlessness with activities to evaluate shortness of breath associated with strenuous activities.

Intervention type: OTHER
Intervention: Daily diary
Description: Subjects will complete a daily diary including the E-RS: COPD and supplemental asthma items for 7 days.

Intervention type: OTHER
Intervention: Sociodemographic questionnaire
Description: Sociodemographic questionnaire will capture subject's demographic characteristics, including age, gender, and the highest level of educational attainment.

Intervention type: OTHER
Intervention: Clinical questionnaire
Description: Clinical questionnaire will capture subject's clinical characteristics including the number of asthma exacerbations in the past 12 months, absenteeism due to asthma in the past month, and the presence of comorbid conditions.